CDKN2A and small cell lung carcinoma: However, in a biomarker-driven phase II umbrella trial for patients with SCLC after platinum-based chemotherapy, a selective small-molecule WEE1 inhibitor AZD1775 monotherapy showed no objective response in SCLC with MYC amplification or co-alterations of CDKN2A and TP53 [179].